Edge Therapeutics Inc(NASDAQ:EDGE) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 3, 2016. Earnings per share were $-0.33. Analysts had estimated an EPS of $-0.38.
In a different note, On May 9, 2016, Credit Suisse said it Maintains its rating on Edge Therapeutics Inc. In the research note, the firm Lowers the price-target to $19.00 per share. The shares have been rated ‘Outperform’ by the firm.
Several Insider Transactions has been reported to the SEC. On Aug 2, 2016, Brian A Leuthner (President and CEO) sold 7,500 shares at $9.54 per share price.Also, On Mar 15, 2016, James Healy (director) purchased 541,343 shares at $7.30 per share price.On Mar 15, 2016, James J Loughlin (director) purchased 3,000 shares at $7.62 per share price, according to the Form-4 filing with the securities and exchange commission.
Edge Therapeutics Inc. is a United States-based biotechnology company which focuses on developing therapies in the management of acute life-threatening neurological conditions. The Company offers Precisa a programmable biodegradable polymer-based development platform. Its product candidates include EG-1962 which completed Phase I/II clinical trial and EG-1964. Its EG-1962 is a polymer-based micro particle containing nimodipine that helps in managing patient outcomes after aneurysmal subarachnoid hemorrhage. Its EG-1964 is used as prophylactic treatment in the management of chronic subdural hematoma (cSDH) to prevent recurrent bleeding on surface of the brain. Its product candidates utilize Precisa which allows it to create therapeutics based on specific physical and chemical properties. Its Precisa enables targeted delivery to the exact site of the injury and provides a controlled drug release to the affected area. It is also developing other product candidate EG-1963.